China Solid Tumor NPP Lead (Associate Director)
Johnson & Johnson Innovation
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at jnj.com.
As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit.
Job Function:
MarketingJob Sub Function:
Strategic MarketingJob Category:
People LeaderAll Job Posting Locations:
Beijing, China, Shanghai, ChinaJob Description:
Job Title: Solid Tumor China NPP Lead/Associate Strategic Marketing Director
Reporting Line
Reports to: APSO Solid Tumor TA Lead
Matrix collaboration with: APSO, OpCo Solid Tumors teams, China R&D (CCT), Medical, Market Access, BD, and Commercial Operations
Purpose of the Role
The China Solid Tumors Strategic Marketing – New Product Planning Lead is accountable for shaping and driving the long‑term pipeline and portfolio strategy for Solid Tumour oncology in China, from early clinical stages through pre‑launch readiness.
This role serves as the strategic “bridge” between global asset development and China’s unique market needs, ensuring future assets, indications, and business models are fit‑for‑China, competitively differentiated, and launch‑ready. The role leads China NPP strategy across key solid tumour disease areas and plays a critical role in influencing global development priorities, lifecycle strategy, and portfolio investment decisions.
Key Responsibilities
1. China Solid Tumours Pipeline & Portfolio Strategy
Own and drive the China Solid Tumours NPP strategy, spanning early to late‑stage assets and indications.
Define China‑specific strategic imperatives, disease area priorities, and portfolio sequencing aligned to unmet medical need and commercial opportunity.
Lead pipeline sufficiency and portfolio gap analysis versus current and future competitive landscapes in China.
Develop and articulate clear China value narratives for pipeline assets to support governance, prioritization, and investment decisions.
2. Early Asset & Indication Shaping
Influence Target Product Profiles (TPPs), indication sequencing, and clinical development strategies to optimize China relevance.
Partner closely with China Compound Team (CCT), APSO DAS lead, and Medical Affairs to ensure early integration of commercial insights.
Provide strategic input at key global development milestones (pre‑IND, Phase I–III, lifecycle extensions).
Identify China‑specific opportunities including biomarkers, precision medicine strategies, combination approaches, and novel access models.
3. Pre‑Launch & Launch Excellence Readiness
Lead China pre‑launch strategic planning for priority solid tumour assets, ensuring seamless transition from NPP to inline teams.
Define future launch archetypes, success metrics, and critical enablers (diagnostics, patient pathways, ecosystem readiness).
Ensure early alignment across Commercial, Medical, Market Access, and Operations on launch ambition and execution model.
4. Cross‑Functional & Global Leadership
Act as the China strategic interface to global and regional Solid Tumours teams.
Lead and influence complex, matrixed cross‑functional teams without direct authority.
Partner with Business Development to assess external opportunities, collaborations, and pipeline expansion options relevant to China.
Represent China perspectives in global governance forums, ensuring China’s voice is clearly articulated and influential.
5. Strategic Planning & Governance
Drive China Solid Tumours long‑range strategic planning (LRFP, BP) from a pipeline and portfolio perspective.
Support senior leadership with high‑quality strategic insights, scenario planning, and decision frameworks.
Ensure all activities are compliant with internal governance, ethics, and regulatory requirements.
Key Stakeholders
AP Solid Tumours DAS & Asset Teams
China Oncology Leadership Team
China R&D / CCT
Medical Affairs, Market Access, Commercial Excellence
Business Development & Strategic Insights
Qualifications & Experience
Required
Bachelor’s degree required; MBA, PhD, PharmD, or MD strongly preferred
Extensive experience in oncology strategic marketing, NPP, portfolio strategy, or commercial strategy
Strong understanding of China oncology market dynamics, including policy, access, and competitive environment
Proven ability to influence global development and lifecycle strategy without direct reporting lines
Experience across early and late‑stage pipeline assets
Preferred
Solid tumour therapeutic area expertise (e.g., lung, GU, GI, bladder, CRC, breast, head & neck)
Experience working in matrixed global–regional–local organizations
Exposure to precision medicine, diagnostics, or novel modalities
Strong strategic storytelling and executive communication skills
Critical Capabilities
Enterprise‑level strategic thinking
Strong commercial and clinical acumen
High influence and stakeholder management capability
Comfort with ambiguity and early‑stage decision‑making
Ability to translate complexity into clear strategic choices
Success Measures
Strength and clarity of China Solid Tumours pipeline strategy
Degree of China influence on global asset and indication decisions
Quality of pre‑launch readiness for priority assets
Leadership impact across cross‑functional and global stakeholders
Required Skills:
Preferred Skills:
Brand Marketing, Brand Marketing, Brand Positioning Strategy, Business Alignment, Business Storytelling, Business Valuations, Cross-Functional Collaboration, Customer Intelligence, Data Analysis, Data-Driven Decision Making, Developing Others, Digital Strategy, Execution Focus, Financial Analysis, Go-to-Market Strategies, Inclusive Leadership, Industry Analysis, Leadership, Market Research, Negotiation, Problem Solving, Product Development Lifecycle, Product Portfolio Management, Product Strategies, Program Management {+ 2 more}